It is speculated that FAM134B, CCPG1, and TEX264 are receptors for common ER-phagy in tumor development, while SEC62 may be more significant in the recovery process after anticancer compound treatment, and RTN3L may have a hand in the degradation of the tubular ER. This evidence concerns the gene SEC62 and neoplasm.